Future Market Insights (FMI) has released an insightful market research report highlighting the rapid growth of the global fuchs endothelial corneal dystrophy (FECD) market. According to the report, the market’s value has surged to USD 180 billion in 2023 and is projected to soar to an impressive USD 370 billion by 2033, reflecting a robust Compound Annual Growth Rate (CAGR) of 7.5% over the forecast period.
Several key factors are driving this remarkable market expansion. Firstly, the prevalence of Fuchs’ endothelial corneal dystrophy is on the rise, significantly boosting the demand for advanced treatment options. Additionally, the demographic shift towards an aging population is contributing to the increased incidence of this condition, further propelling market growth. As the global population ages, the prevalence of age-related diseases like FECD is expected to climb, necessitating more comprehensive healthcare solutions.
Prepare To Thrive And Conquer New Horizons With Our Sample Report – Get It Now
Governmental and private organizations are intensifying efforts to raise awareness about eye disorders and promote corneal donation, which is expected to significantly contribute to market growth. Additionally, the surge in research focusing on cellular treatment techniques and the growing demand for comprehensive eye care services are anticipated to create lucrative opportunities within the fuchs endothelial corneal dystrophy market landscape.
The report provides comprehensive insights into the competitive landscape, market dynamics, and key trends shaping the global fuchs endothelial corneal dystrophy market. It offers actionable intelligence to industry stakeholders, enabling them to make informed decisions and capitalize on emerging opportunities.
Key Takeaways from the Market Study:
- FMI projects the global Fuchs Endothelial Corneal Dystrophy (FECD) market to expand at a 7.5% value CAGR by 2033
- The global Fuchs Endothelial Corneal Dystrophy (FECD) market is estimated at a market value of USD 180 Billion
- The global Fuchs Endothelial Corneal Dystrophy (FECD) is expected to garner a market value of USD 370 Billion
- As per Future Market Insights, the Asia Pacific is expected to grow at a CAGR of 7% in the assessment period 2023-2033.
- North America is expected is expected to grow at a CAGR of 7.4% in the assessment period 2023-2033.
- Europe is expected to grow at a CAGR of 7.3% in the assessment period 2023-2033.
- The hospitals segment is expected to hold the largest market share for lucrative Fuchs Endothelial Corneal Dystrophy (FECD) market in the forecast period 2023-2033.
“Asia-Pacific is predicted to rise over the projected period of 2023-2033 due to increased R&D activities, increased investment in the healthcare industry, and more government assistance,” says an analyst at FMI
Transform Your Insights the Comprehensive Report Now
Market Competition:
Key players in the Fuchs Endothelial Corneal Dystrophy (FECD) market are
- Kowa Pharmaceuticals
- Trefoil Therapeutics
- Alcon
- Emmecell
- Santen
- AJL Ophthalmic SA
- Massachusetts Eye and Ear
- KeraMed, Inc.
- Presbia Plc
In May 2022, SEGLENTIS® C-IV is now available for purchase through Kowa Pharmaceuticals America, Inc.
Key Segments Profiled in the Fuchs Endothelial Corneal Dystrophy (FECD) Market Industry Survey:
By Treatment:
- Phototherapeutic Keratectomy
- Amniotic Membrane Transplants
- Anterior Stromal Puncture
- Conjunctival Flaps
By Diagnosis:
- Slit-lamp Examination
- Molecular Genetic Tests
- Pachymetry
By End User:
- Hospitals
- ASCs
- Others
By Region:
- North America
- Latin America
- Western Europe
- Eastern Europe
- Asia Pacific
- Middle East & Africa (MEA)
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
